cervical cancer

Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.

In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.

The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.

The Cobas HPV Test is now approved for use as a primary screening test with BD's SurePath and Hologic's ThinPrep PreservCyt Solution.

A team of researchers in Japan used a noninvasive prenatal testing platform to detect copy number alterations in about 20 percent of gynecological cancers they tested.

Significantly fewer women screened with HPV testing alone had high-grade pathologies four years later compared to those receiving cytology testing.

Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify cervical cancer patients who may benefit from the anti-PD1 immunotherapy.

IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.